AWE18
What is it?
Experimental cyclic Ala/Glu/Trp peptidomimetic discussed in the development literature. Its evidence must remain separate from CP-88.
Research context
Experimental cyclic Ala/Glu/Trp peptidomimetic discussed in the development literature. Its evidence must remain separate from CP-88.
- Working classification
- Peptide / preparation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —See preparation-specific records; human benefit not established here
- Study methods
- —Source-specific designs and limitations below
- Independent replication
- —Related reports are not automatically independent evidence
- Source access
- —Linked publications; access and review scope shown per record
- Safety evidence
- —Clinical safety, product equivalence and interactions not established by this collection
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Explore the expanded peptide research collection and unresolved source trails ↗
Linked sources
Explore the research map and unresolved leads ↗
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Defined synthetic peptide / analogue
Vladislav Deigin, Natalia Linkova, Olga Volpina · International Journal of Molecular Sciences 24(17):13534
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
- Population / setting
- Source-specific experimental population
- What was checked
- Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.
Limitations & review scope
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.